Current Affairs - International - Discussion

Wave Life Sciences, based in the United States, achieved a significant milestone by becoming the first company to treat a genetic condition through RNA editing at the clinical level. This technique, involving the editing of Messenger RNA (mRNA) after it is transcribed from DNA but before protein synthesis, allows for precise genetic modifications that can address specific mutations. By targeting conditions like α-1 antitrypsin deficiency (AATD) with RNA editing, this approach holds potential for treating a variety of genetic disorders, including Huntington's disease and Duchenne muscular dystrophy, promising advancements in genetic therapies.